**SUMMARY REPORT FOR PUBLICATION**

**February 2023 Promotion of DCVax-L by Northwest Biotherapeutics, Inc**

MHRA received a complaint about a news article on the online version of the Cambridge Independent (UK) dated 25 February 2022 about Northwest Biotherapeutics’ manufacturing facility in Sawston and about Northwest Biotherapeutics’ social media channels. The complainant alleged that Northwest Biotherapeutics was advertising unlicensed medicines.

In order to determine any media activity undertaken by Northwest Biotherapeutics that may have led to the publication of the article in the Cambridge Independent, MHRA contacted Northwest Biotherapeutics. They responded to explain the media engagement about the research facility that had been done with the publication. MHRA could find no evidence to suggest that the information provided by the company to the media publication was promotional in nature. Northwest Biotherapeutics also stated that they had not engaged in social media activity since 2018. The company said that they take its regulatory requirements extremely seriously. MHRA did not uphold the complaint.

We contacted the Cambridge Independent to highlight guidance for journalists on reporting to the public on medicines as outlined in [Appendix 5](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/956858/Appendix_5.pdf) of the [MHRA Blue Guide](https://www.gov.uk/government/publications/blue-guide-advertising-and-promoting-medicines) on the Advertising and Promotion of Medicines in the UK.